- Home
- KRMD vs CTNM Comparison
KRMD vs CTNM Comparison
Compare KRMD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRMD
- CTNM
- Stock Information
- Founded
- KRMD 1980
- CTNM 2009
- Country
- KRMD United States
- CTNM United States
- Employees
- KRMD N/A
- CTNM N/A
- Industry
- KRMD Medical/Dental Instruments
- CTNM
- Sector
- KRMD Health Care
- CTNM
- Exchange
- KRMD Nasdaq
- CTNM Nasdaq
- Market Cap
- KRMD 134.3M
- CTNM 122.9M
- IPO Year
- KRMD N/A
- CTNM 2024
- Fundamental
- Price
- KRMD $3.62
- CTNM $3.88
- Analyst Decision
- KRMD Strong Buy
- CTNM Strong Buy
- Analyst Count
- KRMD 4
- CTNM 4
- Target Price
- KRMD $4.63
- CTNM $22.50
- AVG Volume (30 Days)
- KRMD 456.1K
- CTNM 213.2K
- Earning Date
- KRMD 08-06-2025
- CTNM 08-12-2025
- Dividend Yield
- KRMD N/A
- CTNM N/A
- EPS Growth
- KRMD N/A
- CTNM N/A
- EPS
- KRMD N/A
- CTNM N/A
- Revenue
- KRMD $35,083,740.00
- CTNM N/A
- Revenue This Year
- KRMD $18.16
- CTNM N/A
- Revenue Next Year
- KRMD $14.60
- CTNM N/A
- P/E Ratio
- KRMD N/A
- CTNM N/A
- Revenue Growth
- KRMD 19.65
- CTNM N/A
- 52 Week Low
- KRMD $1.86
- CTNM $3.35
- 52 Week High
- KRMD $5.05
- CTNM $21.92
- Technical
- Relative Strength Index (RSI)
- KRMD 68.65
- CTNM N/A
- Support Level
- KRMD $3.45
- CTNM N/A
- Resistance Level
- KRMD $3.77
- CTNM N/A
- Average True Range (ATR)
- KRMD 0.22
- CTNM 0.00
- MACD
- KRMD 0.02
- CTNM 0.00
- Stochastic Oscillator
- KRMD 85.48
- CTNM 0.00
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.